Manila Times Business
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cellsData analysis is now underway to support future regulatory submission in Japan BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Colombia moves to ban female genital mutilation
1h ago
Alas Pilipinas bows out of AVC Women’s Cup medal contention after loss to Taiwan
1h ago
Family lawyer seeks immigration watchlist order vs Ateneo coach in Aurora drowning case
1h ago
Global Fatty Liver Day 2026 builds on WHO Momentum to Drive Urgent Action on Steatotic (fatty) Liver Disease
1h ago